ResMed Inc. (NYSE:RMD) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET

Company Participants

Amy Wakeham - Chief Investor Relations Officer
Michael Farrell - Chairman and Chief Executive Officer
Brett Sandercock - Chief Financial Officer

Conference Call Participants

Laura Sutcliffe - UBS
Craig Wong-Pan - RBC
David Low - JPMorgan
Saul Hadassin - Barrenjoey Capital
Anthony Petrone - Mizuho
Daniel Hurren - MST Marquee
Mike Matson - Needham & Company
Brett Fishbin - KeyBanc Capital Markets
Suraj Kalia - Oppenheimer
Lyanne Harrison - Bank of America
Andrew Paine - CLSA

Operator

Hello, and welcome to the Q1 Fiscal Year 2025 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we'll conduct a question-and-answer session. Please note this conference call is being recorded.

I'll now turn the call over to Amy Wakeham, Chief Investor Relations Officer. Amy, you may begin.

Amy Wakeham

Great. Thank you, Kevin. Hi, everyone, and welcome to ResMed's first quarter fiscal year 2025 earnings call. As Kevin said, we are live webcasting this call and the replay will be available on the Investor Relations section of our corporate website later today. Our earnings press release and presentation are both available online now.

During today's call, we will discuss several non-GAAP measures that we believe provide helpful information for investors. This information is not intended to be considered in isolation or as a substitute for the reported GAAP financial information. We encourage you to review the supporting schedules in today's earnings press release to reconcile these non-GAAP measures with the GAAP reported numbers.

In addition, our discussion today will include forward-looking statements, including but not limited to expectations about our future financial and operating performance. We make these statements based on reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today.

I'll now turn the call over to ResMed's Chairman and CEO, Mick Farrell.

Michael Farrell

Thanks, Amy, and welcome to all of our shareholders for joining us today as we review ResMed's first quarter results for fiscal year 2025.

I'm pleased to report another strong quarter of growth across all of our business segments. We've seen solid revenue growth, improved gross margins, and disciplined investments in both SG&A and R&D, resulting in very strong profit performance. The results we are presenting today reflect the hard work of the 10,000-plus ResMedians operating in over 140 countries worldwide. And the dedication they bring to improving the lives of patients, physicians, providers, and all of our customers every day.